The hidradenitis suppurativa (HS) treatment market is set to surpass USD 763.6 million in 2023 and is projected to reach an impressive USD 1,240.9 million by 2033. This growth represents a compound annual growth rate (CAGR) of 4.97% over the forecast period.
Hidradenitis suppurativa is a chronic inflammatory skin condition characterized by painful lumps, abscesses, and scarring, significantly impacting patients’ quality of life. The increasing prevalence of HS, along with a growing understanding of its underlying mechanisms, is driving demand for effective treatment options.
As healthcare providers and researchers continue to focus on developing innovative therapies, the HS treatment market is anticipated to expand significantly. Enhanced awareness of the condition and the importance of early diagnosis are also expected to contribute to market growth.
Revenue growth of the global Hidradenitis suppurativa (HS) treatment market is significantly propelled by factors such as the increasing prevalence of chronic diseases, rapid advancements in the healthcare and medical sector, high adoption of the latest tools and techniques, and increasing funds by several public and private sectors.
In addition, growing focus on drug development, rising demand for precision medicine, high adoption of home care settings and point-of-care diagnostics, and growing investments in research and development activities are anticipated to drive global market revenue growth during the forecast period.
Market Competition
The global Hidradenitis suppurativa (HS) treatment market is highly competitive due to the presence of a large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition. The major players in the market are Inflarx, Novartis Pharmaceuticals, Incyte Corporation, UCB Biopharma SPRL, Janssen Pharmaceuticals, Amgen, Chemocentryx, Priovant Therapeutics/Pfizer, Anaptysbio, Abbvie, Acelyrin, Aclaris Therapeutics, Boehringer Ingelheim, Eli Lilly, Moonlake Immunotherapeutics, and Aristea Therapeutics.
Some recent developments in this industry are:
- In June 2022, Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus were announced by Roivant and Pfizer.
- In February 2021, AbbVie Inc. received FDA approval for HUMIRA (adalimumab), which can be used to treat moderate to severe hidradenitis suppurative (HS) treatment.
- In March 2022, MoonLake started the Phase II trial of nanobody, sonelokimab for treating moderate-to-severe hidradenitis suppurative (HS) treatment (HS). Sonelokimab has the potential to treat inflammatory diseases by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that cause inflammation in the body.
Key Companies Profiled
- InflaRx N.V
- Novartis A.G
- Incyte Corporation
- UCB Biopharma SPRL
- Janssen Pharmaceuticals
- Amgen Inc.
- ChemoCentryx
- Priovant Therapeutics
- AnaptysBio
- AbbVie Inc.
- ACELYRIN
- Aclaris Therapeutics Inc.
- Boehringer Ingelheim
- Eli Lilly and Company
- MoonLake Immunotherapeutics
- Aristea Therapeutics
Key Segments Profiled in the Hidradenitis Suppurativa (HS) Treatment Market Industry Survey
By Clinical Stages:
- Hurley Stage 1- Low
- Hurley Stage 2- Moderate
- Hurley Stage 3- High
By Treatment Type:
- Medication
- Biologics
- Antibiotics
- Hormonal Therapy
- Immune Suppurativa Drugs
- Zinc Supplements
- Pain Medications
- Surgery
By Route of Administration:
- Oral
- Tropical
By End Users:
- Hospitals
- Homecare
- Specialty Clinics
By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
